Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.
By Gina Columbus
Advertisement
Articles by By Gina Columbus
Advertisement
Latest Updated Articles
Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALLPublished: April 21st 2017 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data
2
FDA Activity Recap: October 2025 Features New Platform Technology Designation, RDEA Pilot Program Selection, and More
3
